649 related articles for article (PubMed ID: 15905560)
21. Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.
Khare P; Jaiswal AK; Tripathi CD; Sundar S; Dube A
Clin Exp Immunol; 2016 Aug; 185(2):165-79. PubMed ID: 26898994
[TBL] [Abstract][Full Text] [Related]
22. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
23. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
Ghosh A; Zhang WW; Matlashewski G
Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
[TBL] [Abstract][Full Text] [Related]
24. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
Agallou M; Margaroni M; Karagouni E
Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
[TBL] [Abstract][Full Text] [Related]
25. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
26. TLR-mediated distinct IFN-γ/IL-10 pattern induces protective immunity against murine visceral leishmaniasis.
Paul J; Karmakar S; De T
Eur J Immunol; 2012 Aug; 42(8):2087-99. PubMed ID: 22622993
[TBL] [Abstract][Full Text] [Related]
27. Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters.
Baharia RK; Tandon R; Sahasrabuddhe AA; Sundar S; Dube A
PLoS One; 2014; 9(6):e97911. PubMed ID: 24926878
[TBL] [Abstract][Full Text] [Related]
28. Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.
Sabur A; Bhowmick S; Chhajer R; Ejazi SA; Didwania N; Asad M; Bhattacharyya A; Sinha U; Ali N
Front Immunol; 2018; 9():18. PubMed ID: 29441060
[TBL] [Abstract][Full Text] [Related]
29. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
[TBL] [Abstract][Full Text] [Related]
30. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.
Alexander J; Carter KC; Al-Fasi N; Satoskar A; Brombacher F
Eur J Immunol; 2000 Oct; 30(10):2935-43. PubMed ID: 11069076
[TBL] [Abstract][Full Text] [Related]
31. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
32. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
Lakshmi BS; Wang R; Madhubala R
Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
[TBL] [Abstract][Full Text] [Related]
33. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response.
Melby PC; Chandrasekar B; Zhao W; Coe JE
J Immunol; 2001 Feb; 166(3):1912-20. PubMed ID: 11160239
[TBL] [Abstract][Full Text] [Related]
34. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
35. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani.
Melby PC; Yang YZ; Cheng J; Zhao W
Infect Immun; 1998 Jan; 66(1):18-27. PubMed ID: 9423834
[TBL] [Abstract][Full Text] [Related]
36. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
38. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
39. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
[TBL] [Abstract][Full Text] [Related]
40. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.
Engwerda CR; Murphy ML; Cotterell SE; Smelt SC; Kaye PM
Eur J Immunol; 1998 Feb; 28(2):669-80. PubMed ID: 9521077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
